PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.

Item

http://www.wikidata.org/entity/Q53398122

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.

@en

PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.

@nl

type

Item

label

PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.

@en

PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.

@nl

prefLabel

PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.

@en

PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.

@nl

P1476

PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer

@en

P2093

Ion Cristóbal

http://www.w3.org/2001/XMLSchema#string

Jesús García-Foncillas

http://www.w3.org/2001/XMLSchema#string

Juan Madoz-Gúrpide

http://www.w3.org/2001/XMLSchema#string

Paula González-Alonso

http://www.w3.org/2001/XMLSchema#string

Rebeca Manso

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting the adaptive molecular landscape of castration-resistant prostate cancer

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.

Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications

Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway.

alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis.

Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model.

Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.

Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells.

Cancerous inhibitor of protein phosphatase 2A promotes premature chromosome segregation and aneuploidy in prostate cancer cells through association with shugoshin.

P2888

s13277-015-3849-5

P304

5753-5755

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13277-015-3849-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Federico Rojo

P577

2015-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26234767

http://www.w3.org/2001/XMLSchema#string